Compare Merck & Co., Inc. (MRK) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Schwab US Large Cap Growth ETF — how do they compare? Merck & Co., Inc. trades at $132.78 (market cap $321.77B), while Schwab US Large Cap Growth ETF trades at $35.65. The key difference: Merck & Co., Inc. pays a 2.61% dividend while Schwab US Large Cap Growth ETF pays none. Which is the better fit depends on your goals.
| MRK | SCHG | |
|---|---|---|
Market Cap | $321.77B | — |
Sector | Health | Sector/Thematic |
52-Week High | $131.84 | $35.83 |
52-Week Low | $77.60 | $28.10 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
SCHG trades at $35.63, down 0.56% today, with a bullish technical outlook driven by strong moving average signals. The ETF's concentrated exposure to AI leaders like Nvidia and Microsoft positions it for growth, though high RSI readings suggest potential near-term consolidation. Recent news highlights institutional activity and the fund's low 0.04% expense ratio as key advantages.
The outlook remains positive given SCHG's alignment with AI infrastructure growth, but risks include heavy tech concentration and sensitivity to interest rates. Wall Street sentiment is mixed, with some analysts citing valuation concerns while others emphasize long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
